Kolexia
Aladjidi Nathalie
Pédiatrie
Hôpital Pellegrin
Bordeaux, France
167 Activités
18 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Thrombopénie Lymphomes Purpura thrombopénique idiopathique Anémie hémolytique auto-immune Histiocytose Histiocytose à cellules de Langerhans Anémie Anémie hémolytique Lymphome à grandes cellules anaplasiques

Industries

Sanofi
10 collaboration(s)
Dernière en 2023
Novartis
2 collaboration(s)
Dernière en 2020
PHARMING GROUP N.V.
1 collaboration(s)
Dernière en 2023
Takeda Pharmaceutical
1 collaboration(s)
Dernière en 2021

Dernières activités

Autoimmune cytopenia and Kabuki syndrome in paediatrics: Insights in 11 patients.
British journal of haematology   03 mars 2024
Antinuclear antibodies associated auto-immune cytopenia in childhood is a risk factor for systemic lupus erythematosus.
Blood   16 janvier 2024
Human inherited CCR2 deficiency underlies progressive polycystic lung disease.
Cell   28 décembre 2023
Autoantibodies against type I IFNs in humans with alternative NF-κB pathway deficiency.
Nature   08 novembre 2023
Fertility and Pregnancy in Patients with Congenital Neutropenia: Experience of the French Severe Chronic Neutropenia Registry in 565 Patients Above Age of 15 Years
65th ASH Annual Meeting Abstracts   02 novembre 2023
Hematological Involvement in Childhood Langerhans Cell Histiocytosis: A Cohort Study of 303 Patients
65th ASH Annual Meeting Abstracts   02 novembre 2023
CHILDREN WITH REFRACTORY HISTIOCYTOSIS TREATED BY MAPKI HAVE A HIGH RISK OF NEURO DEGENERATION: AN INTERNATIONAL STUDY
Abstracts from the 39th Annual Meeting of the Histiocyte Society Held Virtually and In Person in Athens, Greece from October 22–24, 2023   17 octobre 2023
HEMATOLOGICAL INVOLVEMENT IN CHILDHOOD LANGERHANS CELL HISTIOCYTOSIS. A COHORT STUDY OF 303 PATIENTS
Abstracts from the 39th Annual Meeting of the Histiocyte Society Held Virtually and In Person in Athens, Greece from October 22–24, 2023   17 octobre 2023
Real-world experience with CLAIRYG® 50 mg/mL (intravenous immunoglobulin) in children under 12 years with primary immunodeficiency or immmune thrombocytopenia: a post-approval safety study.
Frontiers in pediatrics   02 octobre 2023
Adolescents and young adults with newly diagnosed primary immune thrombocytopenia.
Haematologica   01 octobre 2023